RAMAT GAN, Israel, November 7 – Biop Medical announced it will present its point-of-care cervical cancer detection technology at MEDICA 2017 in Düsseldorf, Germany, November 13-16. The company recently started its second round of investment.
The tool advances cervical cancer diagnosis using optic technology that accurately detects cancerous and pre-cancer lesions in real time. Patients receive an immediate diagnosis without the prolonged waiting time and stress associated with common diagnostic methods. The technology generates a map of diseased lesions to help physicians pinpoint exactly where to perform biopsies.
"With this new precision, physicians can see where to target biopsies and only perform the procedure when necessary," said Biop Medical CEO Ilan Landesman. "Patients gain a more accurate and faster diagnosis while avoiding the painful procedure as well as reduced costs for hospitals and healthcare providers."
Numed, a well established company in business since 1975 provides a wide range of service options including time & material service, PM only contracts, full service contracts, labor only contracts & system relocation. Call 800 96 Numed for more info.
Biop Medical's system consists of two components which are connected to the main control unit. The high definition Biop digital colposcope module offers a high-resolution digital cervix visualization. When the Biop micro-colposcope module is connected, it is directed by an algorithm to the centre of the cervix and then performs a thorough high-magnification inner scan of the cervix.
Using a sterile and disposable cover, the device is inserted until it is in contact with the cervix and projects a full array of light into the full depth of the cervix. The received refractions and reflections off the cervical tissue by the emitted light indicate where cancerous and pre-cancerous lesions are located. When used together, the scans from both components create a color map to help physicians determine where to perform biopsies.
This data can help track the cancer's advancement with results automatically uploaded to the cloud. The platform for aggregating the data was developed with the support of IBM during Biop Medical's time at the IBM Alpha Zone Accelerator.
Biop Medical's technology requires a short and simple training, compared to years of experience required to capably perform cervical cancer diagnosis with a colposcope. "The device is easy to use, light and compact, making it an ideal tool for diagnosing patients. In the developing world, where there are minimal to no screening programs, Biop Medical's "point of care" device is an optimal solution," said Landesman. "With cervical cancer being one of the most common cancers and a leading cause of cancer-related mortality among women, Biop Medical hopes to play an important role in detecting and treating the disease as early as possible."
About Biop Medical
Founded in 2013, Biop Medical is a privately-held company developing technologies that detect epithelium-based cancer in real time with a high rate of accuracy. Biop's flagship product is focused on the identification, classification and diagnosis of cervical cancer. Based in Ramat Gan, Israel, Biop Medical's team consists of experienced members of the biology, physics and optics industries along with senior physicians worldwide. Biop Medical's chairman of the board, Mr. Sidney Braginsky, served as the president of Olympus America Inc. To learn more, visit www.biopmedical.com.